title: Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: The University of Arizona early experience.
abstract: OBJECTIVE
  To evaluate the safety and effectiveness of our new cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) program.
  
  
  METHODS
  Retrospective review of patients with gastrointestinal malignancies who were suitable candidates for CRS and HIPEC between 12/1/2009 and 10/1/2010. All clinicopathologic data were reviewed with a special focus on the surgical outcome and the postoperative morbidity and mortality.
  
  
  RESULTS
  Fourteen patients were identified. Median age was 64 years; seven were female. The primary tumors were: colonic (29%), appendiceal (36%), peritoneal mesothelioma (14%), gastric (7%), adenocarcinoma of unknown primary (7%), and gastrointestinal stromal tumor (7%). Eleven patients (79%) received CRS/HIPEC, three for palliation. Three patients that did not undergo CRS/HIPEC had an average peritoneal cancer index (PCI) of 25. The eight patients that underwent curative CRS/HIPEC had an average PCI of 10 and a completeness of cytoreduction score of 0 (87.5%) or 1 (12.5%). Postoperative morbidity was 36%; the worst adverse event was Grade 3 ileus. Mortality rate was 0%.
  
  
  CONCLUSIONS
  CRS with HIPEC is safe and feasible at tertiary institutions with fledgling programs. PCI is an accurate predictor of surgical outcomes.
authors: Ioannis T Konstantinidis, Christine Young, Vassiliki L Tsikitis, Tun Jie, Evan S Ong, Department of Surgery, The University of Arizona College of Medicine, 1501 N. Campbell Av. PO Box 245131, Tucson, AZ 85724-5131, United States.
authors: Ioannis T
authors: IT
authors: Konstantinidis
authors: Christine
authors: C
authors: Young
authors: Vassiliki L
authors: VL
authors: Tsikitis
authors: Ellyn
authors: E
authors: Lee
authors: Tun
authors: T
authors: Jie
authors: Evan S
authors: ES
authors: Ong